JPRN-UMIN000008389已完成2 期
Phase II study of Trastuzuman in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Facter Receptor type-2 (HER-2)-positive Advanced Gastric Cancer - "Trastuzumab, TS-1 plus Platinum ACtivity Evaluation" T-SPACE study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who received radiotherapy within 2 weeks before enrollment. 2) Patients with uncontrollable ascites, pleural effusion or pericardial effusion. 3) Patients with symptomatic brain metastases or carcinomatous meningitis. 4) Patients with other active malignancies. 5) Patients with active infections. 6) Patients with serious complications. 7) Patients with interstitial pneumonia or pulmonary fibrosis detected by chest X-ray. 8) Patients with a history of serious drug allergy. 9) Patients who receive continuous corticosteroid administration. 10) Patients who need to receive flucytosine. 11) Patients who need to receive continuous phenytoin or warfarin administration. 12) Patients with serious mental problem. 13) Pregnant or lactating female. 14) HBs antigen positive patients 15) Other patients evaluated to be inadequate to participate in this study by investigators.
研究者
相似试验
招募中
不适用
Additional TR study on Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinomaHER2 positive gastric and gastroesophageal junction adenocarcinomaJPRN-jRCT1030210361Shitara Kohei37
尚未招募
不适用
PHASE I STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS, FOLLOWED BY A RANDOMIZED, OPEN-LABEL PHASE II STUDY OF TRASTUZUMAB EMTANSINE AND CAPECITABINE VERSUS TRASTUZUMAB EMTANSINE ALONE IN HER2-POSITIVE METASTATIC BREAST CANCER-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-082-14F. HOFFMANN-LA ROCHE LTD.,
招募中
不适用
A phase II clinical study of trastuzumab in combination with capecitabine and cisplatin (XP) in patients with tissue HER2-negative but serum HER2-positive advanced gastric cancerNeoplasmsKCT0004391Asan Medical Center28
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45